Biomarin Pharmaceutical Inc Earnings

The next earnings date for Biomarin Pharmaceutical Inc is October 27, 2025.

They are scheduled to announce earnings before the market opens that day.

Analyst Estimates of Biomarin Pharmaceutical Inc Earnings

Report Date	Estimated Earnings Per Share
10/27/2025	$0.82

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Biomarin Pharmaceutical Inc Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
04/22/2025	Before Market	$1.13	73.39%
02/20/2025	Before Market	$0.92	24.56%
10/29/2024	After Market	$0.55	5.77%
08/05/2024	After Market	$0.56	60.00%
04/24/2024	After Market	$0.46	31.43%
02/22/2024	After Market	$0.18	-21.74%
11/01/2023	After Market	$0.21	-8.70%
07/31/2023	After Market	$0.29	26.09%
04/26/2023	After Market	$0.27	50.00%
02/27/2023	After Market	$-0.00	98.14%
10/26/2022	After Market	$-0.04	-300.00%
08/03/2022	After Market	$0.15	36.36%
04/27/2022	After Market	$0.18	5.88%
02/23/2022	After Market	$-0.32	0.00%
10/27/2021	After Market	$-0.20	20.00%
07/28/2021	After Market	$0.07	163.64%
04/29/2021	After Market	$0.09	228.57%
02/25/2021	After Market	$0.12	163.16%
11/05/2020	After Market	$4.01	223.39%
08/04/2020	After Market	$-0.02	80.00%
04/29/2020	After Market	$0.44	780.00%
02/26/2020	After Market	$0.08	233.33%
10/23/2019	After Market	$0.30	400.00%
08/01/2019	After Market	$-0.21	-90.91%
04/25/2019	After Market	$-0.32	-68.42%
02/21/2019	After Market	$-0.02	92.00%
10/25/2018	After Market	$-0.07	68.18%
08/02/2018	After Market	$-0.21	-23.53%
04/25/2018	After Market	$-0.25	-47.06%
02/22/2018	After Market	$-0.40	-73.91%
10/26/2017	After Market	$-0.07	50.00%
08/02/2017	After Market	$-0.21	0.00%
05/04/2017	After Market	$-0.09	68.97%
02/23/2017	After Market	$-0.53	-39.47%
10/27/2016	After Market	$-0.26	33.33%
08/04/2016	After Market	$1.08	307.69%
04/28/2016	After Market	$-0.53	36.90%
02/25/2016	After Market	$0.39	-60.61%
10/29/2015	After Market	$-0.57	12.31%
08/03/2015	After Market	$-0.43	18.87%
04/30/2015	After Market	$-0.38	28.30%
02/25/2015	After Market	$-0.47	20.34%
10/23/2014	After Market	$-0.38	-65.22%
07/30/2014	---	$-0.22	47.62%
05/01/2014	---	$-0.33	28.26%
02/26/2014	---	$-0.43	-22.86%
10/24/2013	---	$-0.38	-26.67%
07/25/2013	---	$-0.15	48.28%
04/25/2013	---	$-0.31	-6.90%
02/21/2013	---	$-0.43	-59.26%
10/25/2012	---	$-0.04	80.00%
08/01/2012	---	$-0.27	-28.57%
04/26/2012	---	$-0.21	-50.00%
02/16/2012	---	$-0.23	-109.09%
10/27/2011	---	$-0.14	-27.27%
07/28/2011	---	$-0.05	54.55%
04/28/2011	---	$-0.04	60.00%
02/17/2011	---	$0.01	150.00%
10/28/2010	---	$1.68	16,900.00%
08/02/2010	---	$-0.01	-133.33%
04/29/2010	---	$0.01	---
02/23/2010	---	$0.05	400.00%
10/28/2009	---	$0.06	500.00%
07/30/2009	---	$0.01	200.00%
04/30/2009	---	$-0.13	-8.33%
02/18/2009	---	$0.21	-19.23%
10/28/2008	---	$0.01	-66.67%
08/05/2008	---	$0.04	33.33%
04/29/2008	---	$0.02	140.00%
02/26/2008	---	$0.03	-25.00%
11/01/2007	---	$-0.05	50.00%
08/07/2007	---	$-0.04	33.33%
04/30/2007	---	$-0.10	9.09%
02/20/2007	---	$-0.11	15.38%
11/01/2006	---	$-0.08	38.46%
08/02/2006	---	$-0.02	81.82%
05/03/2006	---	$-0.13	38.10%
02/23/2006	---	$-0.20	9.09%
11/01/2005	---	$-0.21	25.00%
08/01/2005	---	$-0.33	5.71%
05/05/2005	---	$-0.35	0.00%
02/23/2005	---	$-0.23	30.30%
11/03/2004	---	$-0.40	-11.11%
08/09/2004	---	$-0.28	3.45%
05/04/2004	---	$-0.31	0.00%
02/03/2004	---	$-0.40	-5.26%
11/04/2003	---	$-0.33	15.38%
08/05/2003	---	$-0.14	12.50%
05/05/2003	---	$-0.35	-25.00%
02/09/2003	---	$-0.36	-2.86%
10/31/2002	---	$-0.32	-3.23%
08/01/2002	---	$-0.27	6.90%
05/07/2002	---	$-0.51	-54.55%
02/25/2002	---	$-0.34	-13.33%
10/26/2001	---	$-0.26	13.33%
07/27/2001	---	$-0.30	-15.38%
04/27/2001	---	$-0.26	0.00%
02/22/2001	---	$-0.28	15.15%
10/30/2000	---	$-0.23	20.69%
07/28/2000	---	$-0.19	29.63%
04/28/2000	---	$-0.34	-30.77%
02/18/2000	---	$-0.26	0.00%
11/01/1999	---	$-0.24	-9.09%

More About Biomarin Pharmaceutical Inc

Website

https://www.biomarin.com

Country

USA

Full Time Employees

3,040

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

“Biomarin Pharmaceutical Inc Earnings” Can Refer to the Biomarin Pharmaceutical Inc Earnings Date

Some people say “Biomarin Pharmaceutical Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Biomarin Pharmaceutical Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Biomarin Pharmaceutical Inc Stock on the Earnings Date

If you own Biomarin Pharmaceutical Inc stock (BMRN) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Biomarin Pharmaceutical Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Biomarin Pharmaceutical Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Biomarin Pharmaceutical Inc Earnings

You can contact us any time if you would like to ask questions about Biomarin Pharmaceutical Inc earnings or anything else related to the stock market.